Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.
|Podcasts|May 21, 2019
A Patient With Medication-Resistant Atrial Fibrillation and Autonomic Dysfunction
Author(s)Heidi Moawad, MD
A patient with worsening atrial fibrillation experiences improvement of his symptoms and heart rate with chiropractic manipulation. More in this podcast.
Advertisement
CASE REPORT
An elderly patient with worsening atrial fibrillation experiences improvement of his symptoms and heart rate with chiropractic manipulation. How would you explain his response?
Heidi Moawad, MD interviews Ryan Haeley, DO, owner of
Advertisement
Related to this article
A. Blake Buletko, MD, and Galina Gheihman, MD, discuss their career paths in neurology, the role of mentorship and resilience, and strategies for navigating professional growth as early-career clinician-educators.
The professor of neurology at the University of Cincinnati discussed why disparities persist in secondary stroke prevention and how growing awareness of social determinants of health is helping to close the gap for underserved patients.
The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.
The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends federal support for ALS research and expanded access to investigational therapies, with additional provisions addressing clinical trial oversight and regulatory planning.
New 12-month interim data showed functional gains with BBP-418 vs placebo, consistent benefit across genotype, age, and baseline pulmonary function subgroups, and a safety profile comparable to placebo.
Real-world 12‑month results from WeSMA, a phase 4 study, showed that oral risdiplam is well tolerated in adults with SMA, with stable motor function and consistent safety findings.
A phase 4 study is evaluating whether adults with chronic inflammatory demyelinating polyneuropathy can transition from intravenous immunoglobulin to subcutaneous efgartigimod PH20 without first experiencing disease worsening.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tavapadon for the Treatment of Parkinson Disease
2
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
3
Phase 4 OCTAGON Trial to Test Rapid Steroid Taper With Ravulizumab
4
PETUNIA Study to Track Nipocalimab Use in Pregnancy
5